Diabetes
Conference Coverage
Progress in treating diabetic foot osteomyelitis
News
Progress in Treating Diabetic Foot Osteomyelitis
Conference Coverage
EASD: Once-weekly omarigliptin as effective as daily sitagliptin
Omarigliptin was noninferior to sitagliptin for reducing HbA1c from baseline to week 24 of treatment.
Conference Coverage
EASD: Once-weekly omarigliptin as effective as daily sitagliptin
Omarigliptin was noninferior to sitagliptin for reducing HbA1c from baseline to week 24 of treatment.
Conference Coverage
EASD: Monthly incretin-based therapy shows promise in type 2 diabetes
Once-monthly efpeglenatide therapy was efficacious in patients whose type 2 diabetes was inadequately controlled with metformin.
News
Monthly Incretin-based Therapy Shows Promise in Type 2 Diabetes
Key clinical point: Once-monthly efpeglenatide therapy was efficacious in patients whose type 2 diabetes was inadequately controlled with...
Conference Coverage
EASD: Alirocumab lipid-lowering benefits extend to patients with high-risk diabetes
The benefits of alirocumab seen in the main study population extend to people with diabetes, with no risk for new onset or worsening of diabetes...
News
Lipid-lowering Benefits of Alirocumab Extend to Patients With High-risk Diabetes
Key clinical point: The benefits of alirocumab seen in the main study population extend to people with diabetes, with no risk for new onset or...
Conference Coverage
EASD: Diabetes doubles death risk from many causes
Having diabetes doubles the risk for death from a multitude of causes and shortens affected patients’ life span by 5-7 years, judging from...
Article
Prediabetes and Metabolic Syndrome: Current Trend
Although accreditation for this CE/CME activity has expired, and the posttest is no longer available, you can still read the full article.
...